PEDRO PIEDRA to Antibodies, Monoclonal, Humanized
This is a "connection" page, showing publications PEDRO PIEDRA has written about Antibodies, Monoclonal, Humanized.
Connection Strength
0.415
-
Respiratory Syncytial Virus Disease Burden and Nirsevimab Effectiveness in Young Children From 2023-2024. JAMA Pediatr. 2025 Feb 01; 179(2):179-187.
Score: 0.175
-
Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season - New Vaccine Surveillance Network, October 2023-February 2024. MMWR Morb Mortal Wkly Rep. 2024 Mar 07; 73(9):209-214.
Score: 0.164
-
Prophylactic and therapeutic testing of Nicotiana-derived RSV-neutralizing human monoclonal antibodies in the cotton rat model. MAbs. 2013 Mar-Apr; 5(2):263-9.
Score: 0.076